World's Best Scientists 2026 revealed!
Award Badge
Biology and Biochemistry
UK
2026

D-Index & Metrics

Biology and Biochemistry

D-Index
123
Citations
58819
World Ranking
551
National Ranking
31

Research.com Recognitions

  • 2026 - Research.com Biology and Biochemistry in United Kingdom Leader Award
  • 2025 - Research.com Biology and Biochemistry in United Kingdom Leader Award
  • 2023 - Research.com Biology and Biochemistry in United Kingdom Leader Award
  • 2016 - Fellow of the Royal Society, United Kingdom

Overview

Paul Workman is affiliated with the Institute of Cancer Research in the United Kingdom. Their research primarily spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine. They have contributed extensively to Molecular Biology, Computational Theory and Mathematics, Oncology, Cell Biology, and Economics and Econometrics.

The scientist's work covers a range of topics including:

  • Heat shock proteins research
  • Computational Drug Discovery Methods
  • Endoplasmic Reticulum Stress and Disease
  • Protein Degradation and Inhibitors
  • Click Chemistry and Applications
  • Protein Structure and Dynamics
  • Ubiquitin and proteasome pathways

Among recent publications, they co-authored:

  • "The kinase polypharmacology landscape of clinical PARP inhibitors," 2020, Scientific Reports
  • "canSAR: update to the cancer translational research and drug discovery knowledgebase," 2020, Nucleic Acids Research
  • "Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes," 2023, Journal of Medicinal Chemistry
  • "Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer," 2020, PLoS ONE
  • "Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma," 2020, Journal of Clinical Investigation

They have frequently published in venues including:

  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nucleic Acids Research
  • Nature Communications
  • Clinical Cancer Research

Paul Workman has collaborated regularly with other researchers, notably:

  • Paul A. Clarke
  • Bissan Al-Lazikani
  • Robert te Poele
  • Albert A. Antolín
  • Marissa Powers

In recognition of their contributions, they were awarded the title of Fellow of the Royal Society, United Kingdom, in 2016.

Best Publications

  • Guidelines for the welfare and use of animals in cancer research

    P Workman;E O Aboagye;F Balkwill;A Balmain

  • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

    Georgios Vlachogiannis;Somaieh Hedayat;Alexandra Vatsiou;Yann Jamin

  • Combinatorial drug therapy for cancer in the post-genomic era

    Bissan Al-Lazikani;Udai Banerji;Udai Banerji;Paul Workman

  • The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

    Adrian J. Folkes;Khatereh Ahmadi;Wendy K. Alderton;Sonia Alix

  • Hsp90 molecular chaperone inhibitors: are we there yet?

    Len Neckers;Paul Workman

  • Imaging biomarker roadmap for cancer studies.

    James P.B. O'Connor;Eric O. Aboagye;Judith E. Adams;Hugo J.W.L. Aerts;Hugo J.W.L. Aerts

  • The promise and peril of chemical probes.

    Cheryl H. Arrowsmith;James E. Audia;Christopher Austin;Jonathan Baell

  • Challenges to curing primary brain tumours

    Kenneth Aldape;Kevin M Brindle;Louis Chesler;Rajesh Chopra

  • HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

    Alison Maloney;Paul Workman

  • Discovery of small molecule cancer drugs: Successes, challenges and opportunities

    Swen Hoelder;Paul A. Clarke;Paul Workman

  • Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

    Timothy A Yap;Michelle D Garrett;Mike I Walton;Florence Raynaud

  • Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.

    Paul Workman;Francis Burrows;Len Neckers;Neal Rosen

  • Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1.

    Barry Panaretou;Giuliano Siligardi;Philippe Meyer;Alison Maloney

  • The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

    Martin O Leach;K Brindle;J Evelhoch;John R Griffiths

  • Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

    Udai Banerji;Anne O'Donnell;Michelle Scurr;Simon Pacey

  • NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

    Suzanne A Eccles;Andy Massey;Florence I Raynaud;Swee Y Sharp

  • The Hsp90 molecular chaperone: an open and shut case for treatment

    Laurence H. Pearl;Chrisostomos Prodromou;Paul Workman

  • 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer

    Paul A. Brough;Wynne Aherne;Xavier Barril;Jenifer Borgognoni

  • New approaches to molecular cancer therapeutics.

    Ian Collins;Paul Workman

  • Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

    Florence I. Raynaud;Suzanne Eccles;Paul A. Clarke;Angela Hayes

Frequent Co-Authors

Florence I. Raynaud
Florence I. Raynaud Institute of Cancer Research
Suzanne A. Eccles
Suzanne A. Eccles Institute of Cancer Research
Martin O. Leach
Martin O. Leach Royal Marsden NHS Foundation Trust
Ian Collins
Ian Collins PharmEnable Therapeutics
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Ian Judson
Ian Judson Institute of Cancer Research
Laurence H. Pearl
Laurence H. Pearl University of Sussex
Chrisostomos Prodromou
Chrisostomos Prodromou University of Sussex
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Andrew D.J. Pearson
Andrew D.J. Pearson Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in expanding your studies beyond Biology and Biochemistry, there are several online degree options that align with health and science careers. Many reputable institutions now offer flexible online programs designed for busy students and professionals, making it easier to advance your education wherever you are.

Healthcare leadership roles are in high demand, and doctoral programs for healthcare administration can provide advanced skills to manage hospitals or health systems. For those interested in medication and patient care, enrolling in an online pharmacy school can open doors to pharmaceutical careers.

Movement science is another growing field. You can earn your degree through an exercise science degree online accredited program, which focuses on fitness, rehabilitation, and sports performance. Alternatively, a kinesiology online degree allows you to explore how physical activity impacts health and disease.

With these online pathways, you can build expertise that supports a range of meaningful, in-demand healthcare and life science careers, all while balancing your studies with other commitments.

Best Scientists Citing Paul Workman

Trending Scientists

Recently Published Articles